





All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for (#1 and #2) and #5

Limits Preview/Index History Clipboard Details

• Search History will be lost after eight hours of inactivity.

Search History will be lost after eight hours of inactivity.
To combine searches use # before search number, e.g., #2 AND #6.

• Search numbers may not be continuous; all searches are represented.

• Click on query # to add to strategy

Clear History

Entrez PubMed Overview Help FAQ Tutorial New/Noteworthy
E-Utilities
DubMad Casine

About Entrez

Text Version

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources Order Documents NLM Mobile NLM Catalog NLM Gateway TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov

PubMed Central

Search	Most Recent Queries	Time	Result
#8 Search (#1 and #2) an	d #5	13:02:25	1
#7 Search (#1 and #2) an	d #4	13:01:36	<u>120</u>
#6 Search (#1 and #2) an	d #3	11:28:03	<u>134</u>
#5 Search diabetic gastro	paresis	11:27:46	<u>384</u>
#4 Search hypertension		11:27:31	<u>243167</u>
#3 Search erectile dysfun	ction	11:27:20	<u>11085</u>
#2 Search cgmp		11:27:04	<u>21040</u>
#1 Search (pde 5) or (pde	v) or (phosphodiesterase)	11:26:48	<u>43267</u>

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Write to the Help Desk

Sep 27 2005 04:32:41







All D	atabases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search	PubMed	2.	for				Go	Clear		
		Limits	Preview/Inde	x Histor	y Clipboa	rd Details	`			
		Display Ab					Send to			
About Ent	rez	a b	``							
Text Vers	ion	All: 1	eview: 1 🌋							

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

□1: Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1999 Dec;21(6):493-6.

Related Articles, Links

[Mode of action of sildenafil]

[Article in Chinese]

Wang J, Re J, Wang Z.

Department of Urology, Xuan Wu Hospital, Beijing 100054.

Sildenafil is the first oral therapeutic agent for erectile dysfunction. Sildenafil is a selective inhibitor of cGMP-specific phosphodiesterase (PDE-5). Penile erection involves relaxation of the corpus cavernosum, an event mediated by NO and cGMP. The biological actions of cGMP are terminated by phosphodiesterase enzymes and PDE-5 is the major cGMP metabolising enzyme in this tissue. Sildenafil is relatively safe compared to erection injectables because it does not relax on isolated human corpus cavernosum, and does not cause priapism. Due to the tendency of abuse of sildenafil, its adverse cardiovascular associations with myocardial infaraction, ventricular arrhythmia and hypertension need to be alerted.

Publication Types:

- Review
- Review, Tutorial

PMID: 12567500 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Sep 27 2005 04:32:41







All Da	tabases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	PMC	Journals	Books
Search[PubMed		for				Go	Clear		
		Limits	Preview/Inde	x Histor	y Clipboa	rd Details	`			
		Display A					Send to			
About Entr	ez		•				J			
Text Versi	on	All: 1	Review: 1							

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

☐1: Trends Pharmacol Sci. 2000 Dec;21(12):484-9.

Related Articles, Links

ELSEVIER FULL TEXT ARTICLE

Pharmacotherapy for erectile dysfunction.

Bivalacqua TJ, Champion HC, Hellstrom WJ, Kadowitz PJ.

Department of Urology and Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA. tbivala@tulane.edu

Erectile dysfunction (ED) is defined as the consistent inability to obtain or maintain an erection for satisfactory sexual relations. An estimated 20-30 million men suffer from some degree of sexual dysfunction. The past 20 years of research on erectile physiology have increased our understanding of the biochemical factors and intracellular mechanisms responsible for corpus cavernosal smooth muscle contraction and relaxation, and revealed that ED is predominantly a disease of vascular origin. Since the advent of sildenafil (Viagra), there has been a resurgence of interest in ED, and an increase in patients presenting with this disease. A thorough knowledge of the physiology of erection is essential for future pharmacological innovations in the field of male ED.

Publication Types:

Review

PMID: 11121838 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services

Privacy Statement | Freedom of Information Act | Disclaimer

Sep 27 2005 04:32:41







All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	Books
Search PubMed] for				Go	Clear		
	Limits	Preview/Index	x History	√ Clipboa	rd Details	`			
About Entrez	Display A		·	10w 20	Sort by	Send to	3		
Text Version	All: 1	Review: 0 🛠							

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

☐1: Anesthesiology. 2000 Jun;92(6):1702-12.

&LWWonline

Related Articles, Links

Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.

Weimann J, Ullrich R, Hromi J, Fujino Y, Clark MW, Bloch KD, Zapol WM.

Departments of Anesthesia and Critical Care, Respiratory Care, and Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

BACKGROUND: Phosphodiesterase type 5 (PDE5) hydrolyzes cyclic guanosine monophosphate in the lung, thereby modulating nitric oxide (NO)/cyclic guanosine monophosphate-mediated pulmonary vasodilation. Inhibitors of PDE5 have been proposed for the treatment of pulmonary hypertension. In this study, we examined the pulmonary and systemic vasodilator properties of sildenafil, a novel selective PDE5 inhibitor, which has been approved for the treatment of erectile dysfunction. METHODS: In an awake lamb model of acute pulmonary hypertension induced by an intravenous infusion of the thromboxane analog U46619, we measured the effects of 12.5, 25, and 50 mg sildenafil administered via a nasogastric tube on pulmonary and systemic hemodynamics (n = 5). We also compared the effects of sildenafil (n = 7) and zaprinast (n = 5), a second PDE5 inhibitor, on the pulmonary vasodilator effects of 2.5, 10, and 40 parts per million inhaled NO. Finally, we examined the effect of infusing intravenous 1-NAME (an inhibitor of endogenous NO production) on pulmonary vasodilation induced by 50 mg sildenafil (n = 6). RESULTS: Cumulative doses of sildenafil (12.5, 25, and 50 mg) decreased the pulmonary artery pressure 21%, 28%, and 42%, respectively, and the pulmonary vascular resistance 19%, 23%, and 45%, respectively. Systemic arterial pressure decreased 12% only after the maximum cumulative sildenafil dose. Neither sildenafil nor zaprinast augmented the ability of inhaled NO to dilate the pulmonary vasculature. Zaprinast, but not sildenafil, markedly prolonged the duration of pulmonary vasodilation after NO inhalation was discontinued. Infusion of I-NAME abolished sildenafil-induced pulmonary vasodilation. CONCLUSIONS: Sildenafil is a selective pulmonary vasodilator in an ovine model of acute pulmonary hypertension. Sildenafil induces pulmonary vasodilation via a NO-dependent mechanism. In contrast to zaprinast, sildenafil did not prolong the pulmonary vasodilator action of inhaled NO.

PMID: 10839922 [PubMed - indexed for MEDLINE]

Search	 Search
the Web	 3egicii

Health Home - Help













Enter your search

Home Healthy Living Diseases & Conditions	
Search	All Yahoo! Health 💹 Search
Top Lifestyle Searches on Yahoo! I	Health: fitness, weight loss, relationships, nutrition, pregnancy

October is Breast Cancer Awareness Month

Read Lillie Shockney's breast cancer blog Sponsored by: FEMARA.com

Encyclopedia provided by: Healthwise

Phosphodiesterase-5 inhibitors (PDE-5 inhibitors) for erection problems [Medication]

Topic Contents

Examples

How It Works

Why It Is Used

How Well It Works

Side Effects

What To Think About

References

Credits

Examples

Brand Name

Chemical Name

Viagra

sildenafil citrate

Levitra

vardenafil

Cialis

tadalafil

Phosphodiesterase-5 inhibitors (PDE-5 inhibitors) are taken at least an hour before you plan to be sexually active. PDE-5 inhibitors will result in an erection only if you are sexually stimulated.

(back to top)

How It Works

During an erection, blood fills tissue in the penis, causing it to enlarge and become stiff. The PDE-5 inhibitors relax smooth muscle, allowing the penis to fill with blood.

10/6/2005 1:11:56 PM

Stimulation of the penis is necessary for Levitra and Cialis to work; Viagra can produce a spontaneous erection in those men for whom it is effective.

(back to top)

Why It is Used

PDE-5 inhibitors can be used when an erection problem (erectile dysfunction) is caused by:

<u>Diabetes.</u>
<u>High blood pressure.</u>

Spinal cord injury or other problems affecting nerve function. Prostate surgery.

Side effects of medications.
Emotional or psychological causes.

(back to top)

How Well It Works

PDE-5 inhibitors are effective treatment for erection problems. A review of trials has shown that 83% of men with erection problems who used Viagra had improved erections that allowed them to have intercourse. Initial studies show Levitra and Cialis have rates of success similar to those of Viagra. Viagra has been studied extensively and used by millions of men; its side effects and long-term effects are well recognized. Levitra and Cialis are new drugs in which long-term effects have not been studied.

PDE-5 inhibitors should be taken at least an hour before you plan to be sexually active.

One study found that Cialis, called "the weekend pill," enhanced the ability to have erections for 24 to 36 hours after taking it. ³ Viagra and Levitra usually enable a man to get an erection at any time for 4 or more hours after taking it.

Viagra does not work as well as it would otherwise if you eat a high-fat meal around the time you take it, so many doctors recommend you take it on an empty stomach. Levitra may be slightly less effective if you eat a high-fat meal, but a moderate-fat meal does not reduce its effectiveness; Cialis works without regard to what you eat. 4

(back to top)

Side Effects

Do not take PDE-5 inhibitors if you are taking any medication that contains <u>nitrates</u>, such as nitroglycerin. This combination can lower blood pressure dangerously, possibly leading to a <u>stroke</u>, a <u>heart attack</u>, or death. If you are taking a medication called an alpha-blocker—used to treat high blood pressure or an enlarged prostate—check with your health professional before you take a PDE-5 medication.

Other side effects are fairly uncommon when taking PDE-5 inhibitors. They include:

Headache.
Skin flushing.
Indigestion.
Nasal congestion.

A few men find that PDE-5 inhibitors affect their vision for a few hours after taking it, usually by causing a slight bluish tinge to their vision. A few men become more sensitive to light. These effects go away in a few hours.

10/6/2005 1:11:56 PM

See Drug Reference for a full list of side effects. (Drug Reference is not available in all systems.)

(back to top)

What To Think About

Health experts have debated the use of PDE-5 inhibitors in men with heart disease, because deaths have been reported in men who used Viagra. The 1999 American College of Cardiology/American Heart Association (ACC/AHA) Expert Consensus Document noted that PDE-5 inhibitors may be dangerous for people who: ⁵

Have coronary artery disease (CAD).

Have heart failure and low blood pressure.

Are taking many different drugs for high blood pressure.

However, several studies have reported that some men with heart problems may be able to take PDE-5 inhibitors safely.

One study found no evidence of increased risk of heart attack or CAD in men who use Viagra. ⁶
Another study in men with CAD reported that Viagra does not lead to heart attack and that heart attacks and other cardiovascular problems reported after taking Viagra may be related more to the physical activity of intercourse than to the medication. ⁷

A study of 35 men found that Viagra is safe for men with moderate heart failure. §

Sexual activity is exercise. If you have a heart condition and have not been sexually active for a while, talk with your health professional to make sure you can safely engage in sexual activity.

PDE-5 inhibitors are not prescribed for anyone who may take nitroglycerin in an emergency.

Tell your health professional if you are using PDE-5 inhibitors and are going to have a test for heart disease (such as a stress treadmill test, cardiac catheterization, stress thallium, or stress echocardiography). You should avoid taking PDE-5 inhibitors for 24 to 48 hours before such a test.

When considering PDE-5 inhibitors for erection problems, it is important to include your partner in your discussions.

If you take any medications, discuss PDE-5 inhibitors with your health professional before using them.

PDE-5 inhibitors can be prescribed by any doctor. You do not have to see a doctor who specializes in sexual health. PDE-5 inhibitors are also available on the Internet; if you obtain the medication through this route, you should discuss its use with your doctor.

Viagra costs \$8 to \$10 per pill, and not all insurance plans will cover the cost of the medication. Most insurance plans that do cover Viagra will approve only a limited supply.

Complete the <u>new medication information</u> form to help you understand this medication.

(back to top)

References

Citations

- 1. Webber R (2003). Erectile dysfunction. Clinical Evidence (10): 1003–1011.
- 2. Gresser U, Gleiter CH (2002). Erectile dysfunction: Comparison of efficacy and side effects of the PDE-

10/6/2005 1:11:56 PM

5 inhibitors sildenafil, vardenafil, and tadalafil. European Journal of Medical Research, 7(10): 435-446.

- 3. Porst H, et al. (2003). Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial. Urology, 62(1): 121-125.
- 4. Seftel AD, et al. (2004). Erectile dysfunction: Etiology, evaluation, and treatment options. Medical Clinics of North America, 88(2): 387-416.
- Cheitlin MD, et al. (1999). Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA expert consensus document. Circulation, 99(1): 168-177.
- 6. Shakir SAW, et al. (2001). Cardiovascular events in users of sildenafil: Results from first phase of prescription monitoring in England. BMJ, 322(7287): 651-652.
- 7. Arruda-Olson AM, et al. (2002). Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA, 287(6): 719-725.
- 8. Webster LJ, et al. (2004). Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure. Archives of Internal Medicine, 164(5): 514-520.

(back to top)

Credits

Author

Nancy Bateman

Editor

Renée Spengler, RN, BSN

Associate Editor

Michele Cronen

Associate Editor

Lisa Shaw

Primary Medical Reviewer

Patrice Burgess, MD - Family Medicine

Specialist Medical Reviewer David C.W. Lau, MD, PhD, FRCPC - Endocrinology & Metabolism

Last Updated

February 17, 2005

(back to top)

Author: Nancy Bateman

Medical Review: Patrice Burgess, MD - Family Medicine

David C.W. Lau, MD, PhD, FRCPC - Endocrinology & Metabolism

Last Updated: February 17, 2005



© 1995-2005, Healthwise, Incorporated, P.O. Box 1989, Boise, ID 83701. ALL RIGHTS RESERVED.

This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information. For more information, click here. Privacy Policy. How this information was developed.



Seorch >>

Directory of Services

- > About Us
- Patient Information
 Online Nursery
 Online Pharmacy
 Publications
 Health Calendar
 Employment
 For Employers
 Education/Residencies
- > Ways to Give

Health Alerts

Up-to-date information for a healthier life

Health & Wellness

Healthy Living



Illnesses & Conditions

Information on diseases and health concerns, including symptoms, treatment options, and prevention.

Type 2 Diabetes: Living With Complications

Medications

You may be taking more than one oral medication to treat your type 2 diabetes. You may be taking insulin by injection or through an insulin pump alone or along with oral diabetes medication. Taking these medications as prescribed can help keep your blood sugar levels within your target range. For information on these medications, see the Medications section of the topic Type 2 Diabetes: Living With the Disease.

You may need to take:

- Aspirin. If you are age 30 or older, talk to your health professional about taking a low-dose, or baby, aspirin daily to prevent heart attack, stroke, or other large blood vessel disease (macrovascular disease).¹
- An angiotensin-converting enzyme (ACE) inhibitor, angiotensin II receptor blocker, or other medication if you have high blood pressure or have protein in your urine. These medications can slow or prevent further damage to your kidneys.
- Medications for digestive problems. The type of medication will depend on the problem you are having. For example, if you have gastroparesis, you may take metoclopramide (Reglan), domperidone (available in Europe and Canada), or erythromycin.
- Nonprescription pain relievers, creams, or prescription oral or injection medications if you have pain from peripheral neuropathy.
- Viagra, Levitra, or Cialis if you have erection problems.
 These medications can aggravate heart problems in some people, especially those taking nitrate medications (such as nitroglycerin). Check with your doctor before taking any of these medications.



Topic Overview Health Tools & **FAOs** Cause **Symptoms** What Happens What Increases Your When to Call a Doctor **Exams and Tests Treatment Overview** Prevention **Home Treatment** Medications Surgery Other Treatment Other Places To Get Help Related Information References

Credits

Medication Choices

Medications for some complications include:

- Aspirin after a heart attack or stroke or to prevent these.
- Statins such as atorvastatin (Lipitor), simvastatin (Zocor), or pravastatin (Pravachol), to help prevent heart attack or stroke.
- Angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for diabetic nephropathy.
- Phosphodiesterase-5 inhibitors (PDE-5 inhibitors), such as Viagra, Levitra, or Cialis if you have erection problems.
 Check with your doctor before taking any of these medications.

What to Think About

Keep your blood sugar levels tightly within a safe range by taking your oral diabetes medication (and, in some cases, insulin) as prescribed.

If you have high cholesterol, take cholesterol-reducing medications (such as statins) to keep your LDL cholesterol level less than 100 mg/dL (2.60 mmol/L), your triglyceride level less than 150 mg/dL (1.7 mmol/L), and if possible, your HDL cholesterol level more than 40 mg/dL (1.15 mmol/L) in men. Women may need an HDL level of more than 50 mg/dL.⁷ See the topic High Cholesterol.

If you have high blood pressure, take medications to keep your blood pressure consistently below 130/80 mm Hg. If your systolic blood pressure is between 130 mm Hg and 139 mm Hg or your diastolic blood pressure is between 80 mm Hg and 89 mm Hg, you may try some lifestyle or behavioral therapy for 3 months before starting medication.⁶ For more information, see the topic High Blood Pressure (Hypertension).

Author: Marianne Flagg Last Updated April 27, 2004
Medical Review: Caroline S. Rhoads, MD - Internal Medicine
Alan Dalkin, MD - Endocrinology

© 1995-2004, Healthwise, Incorporated, P.O. Box 1989, Boise, ID 83701. ALL RIGHTS RESERVED.

This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information. For more information, click here.

Printer Friendly Page

© 2005 Danbury Hospital | Danbury Health Systems
24 Hospital Ave, Danbury, CT 08810. Phone: (203) 739-7000
Home | Directions & Parking | Contact Us | Privacy Statement | Disclaimer